Enhancing the Solubility and Transdermal Delivery of Drugs Using Ionic Liquid‐In‐Oil Microemulsions
Source abstract
Abstract
Abstract The development of hydrophobic drug and protein delivery carriers remains a challenge. To synthesize L‐(‐)‐carnitine‐based ionic liquid (IL), this study applies the density functional theory to investigate the hydrogen bonds and van der Waals force that govern L‐(‐)‐carnitine‐based IL formation. An ionic liquid‐in‐oil microemulsion (IL/O ME) is then developed to facilitate the transdermal delivery of proteins and increase the solubility of drugs. IL/O ME is prepared using isopropyl myristate (IPM), Tween 80/Span 20, and L‐(‐)‐carnitine‐based IL. The skin permeation studies conducted using mouse skin show that the insulin permeation percentage of the developed IL/O ME is 3.55 folds higher than that of phosphate‐buffered saline and 2.91 folds better than that of a hydrophilic L‐(‐)‐carnitine‐based IL. In addition, the solubility of two drug molecules, that is, rosiglitazone and bezafibrate, in IL/O ME is at least 49.28 folds higher than their solubility in water or IPM. Therefore, IL/O ME can significantly improve the solubility of drugs and increase the permeability of proteins (e.g., insulin), thus demonstrating a promising potential as a delivery carrier.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ionic liquids properties and applications · Surfactants and Colloidal Systems · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Advanced Welding and Joining Harbin Institute of Technology Shenzhen 518055 P. R. China
Research Centre of Printed Flexible Electronics School of Materials Science and Engineering Harbin Institute of Technology Shenzhen 518055 P. R. China
Division of Chemistry and Biological Chemistry School of Physical and Mathematical Sciences Nanyang Technological University 21 Nanyang Link Singapore 637371 Singapore
Department of Chemistry University of Idaho Moscow ID 83844‐2343 USA
Funding
National Natural Science Foundation of China · China Scholarship Council · National Research Foundation Singapore
References (50)
Show source-provided references
1. 10.1002/adfm.20200425710.1002/adfm.202004257 ↗
2. 10.1002/adma.20190110310.1002/adma.201901103 ↗
3. 10.1002/adfm.20201058710.1002/adfm.202010587 ↗
4. 10.1038/nrd130410.1038/nrd1304 ↗
5. 10.1016/j.ijbiomac.2018.11.23010.1016/j.ijbiomac.2018.11.230 ↗
6. 10.1038/s41598-019-56731-110.1038/s41598-019-56731-1 ↗
7. 10.1039/b907462g10.1039/b907462g ↗
8. 10.1016/j.ejps.2019.10504210.1016/j.ejps.2019.105042 ↗
9. 10.1016/j.colsurfb.2020.11088610.1016/j.colsurfb.2020.110886 ↗
10. 10.1016/j.ijpharm.2020.11933510.1016/j.ijpharm.2020.119335 ↗
11. 10.1039/C9CS00016J10.1039/C9CS00016J ↗
12. 10.1016/j.molliq.2019.11203810.1016/j.molliq.2019.112038 ↗
13. 10.1021/acs.chemrev.6b0077610.1021/acs.chemrev.6b00776 ↗
14. 10.4236/gsc.2014.4100810.4236/gsc.2014.41008 ↗
15. 10.1016/j.drudis.2019.09.01810.1016/j.drudis.2019.09.018 ↗
16. 10.1039/C9CC02812A10.1039/C9CC02812A ↗
17. 10.1021/acs.langmuir.5b0010710.1021/acs.langmuir.5b00107 ↗
18. 10.1016/j.ijpharm.2010.08.03410.1016/j.ijpharm.2010.08.034 ↗
19. 10.1016/j.molliq.2019.11226410.1016/j.molliq.2019.112264 ↗
20. 10.1016/j.ejpb.2019.03.00410.1016/j.ejpb.2019.03.004 ↗
21. 10.1360/SSC-2020-011310.1360/SSC-2020-0113 ↗
22. 10.1021/acssuschemeng.9b0777310.1021/acssuschemeng.9b07773 ↗
23. 10.1208/s12249-014-0103-110.1208/s12249-014-0103-1 ↗
24. 10.1016/j.ejps.2017.09.05210.1016/j.ejps.2017.09.052 ↗
25. 10.1016/j.ijbiomac.2020.02.07210.1016/j.ijbiomac.2020.02.072 ↗
26. 10.1021/acs.jpcb.7b0545410.1021/acs.jpcb.7b05454 ↗
27. 10.1002/adhm.20160141110.1002/adhm.201601411 ↗
28. 10.1016/j.jconrel.2018.07.02910.1016/j.jconrel.2018.07.029 ↗
29. M. J.Frisch G. W.Trucks H. B.Schlegel G. E.Scuseria M. A.Robb J. R.Cheeseman G.Scalmani V.Barone B.Mennucci G. A.Petersson H.Nakatsuji M.Caricato X.Li H. P.Hratchian A. F.Izmaylov J.Bloino G.Zheng J. L.Sonnenberg M.Hada M.Ehara K.Toyota R.Fukuda J.Hasegawa M.Ishida T.Nakajima Y.Honda O.Kitao H.Nakai T.Vreven J. A.MontgomeryJr. J. E.Peralta F.Ogliaro M.Bearpark J. J.Heyd E.Brothers K. N.Kudin V. N.Staroverov T.Keith R.Kobayashi J.Normand K. R.Raghavachari A.Rendell J. C.Burant S. S.Iyengar J.Tomasi M.Cossi N.Rega J. M.Millam M.Klene J. E.Knox J. B.Cross V.Bakken C.Adamo J.Jaramillo R.Gomperts R. E.Stratmann O.Yazyev A. J.Austin R.Cammi C.Pomelli J. W.Ochterski R. L.Martin K.Morokuma V. G.Zakrzewski G. A.Voth P.Salvador J. J.Dannenberg S.Dapprich A. D.Daniels O.Farkas J. B.Foresman J. V.Ortiz J.Cioslowski D. J.Fox Gaussian Inc. Wallingford CT 2013.
30. 10.1002/jcc.2288510.1002/jcc.22885 ↗
31. 10.1016/0263-7855(96)00018-510.1016/0263-7855(96)00018-5 ↗
32. 10.1038/s41387-018-0017-110.1038/s41387-018-0017-1 ↗
33. 10.1016/j.ijpharm.2019.01.02110.1016/j.ijpharm.2019.01.021 ↗
34. 10.1002/chem.20180163110.1002/chem.201801631 ↗
35. 10.1104/pp.111.17842610.1104/pp.111.178426 ↗
36. 10.1016/j.fluid.2016.05.01610.1016/j.fluid.2016.05.016 ↗
37. 10.1039/D0GC01494J10.1039/D0GC01494J ↗
38. 10.1039/c3gc40899j10.1039/c3gc40899j ↗
39. 10.1039/C6GC00584E10.1039/C6GC00584E ↗
40. 10.1039/D0GC01804J10.1039/D0GC01804J ↗
41. 10.1039/D0GC00849D10.1039/D0GC00849D ↗
42. Pramanick S. · Pharma Times · 2013 · 45 · 65
43. 10.1023/B:PHAM.0000016235.32639.2310.1023/B:PHAM.0000016235.32639.23 ↗
44. 10.1016/j.ijpharm.2015.09.06610.1016/j.ijpharm.2015.09.066 ↗
45. 10.1016/j.ejpb.2015.04.03410.1016/j.ejpb.2015.04.034 ↗
46. 10.1007/s12272-012-0711-910.1007/s12272-012-0711-9 ↗
47. 10.1016/j.jmgm.2016.05.00310.1016/j.jmgm.2016.05.003 ↗
48. 10.1016/j.ijpharm.2007.08.05710.1016/j.ijpharm.2007.08.057 ↗
49. 10.1016/j.addr.2007.07.00410.1016/j.addr.2007.07.004 ↗
50. 10.1038/s41565-020-0693-610.1038/s41565-020-0693-6 ↗